Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Zhejiang Shapuaisi Pharmaceutical Co Ltd

603168:SHH

Zhejiang Shapuaisi Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)9.19
  • Today's Change-0.05 / -0.54%
  • Shares traded46.24m
  • 1 Year change-13.30%
  • Beta1.0351
Data delayed at least 15 minutes, as of Nov 05 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the production, research, development and sale of chemical medicine and Chinese patent drugs. The Company's chemical medicine products mainly include Shapuaisi Bendazac Lysine Eye Drops, infusion products and cefixime products. The Company's Chinese patent drugs include kidney tonifying and nerve soothing products, such as Sizi Tianjing Capsules and Compound Gaoshan Hongjingtian Solution. The Company distributes its products in domestic market.

  • Revenue in CNY (TTM)505.58m
  • Net income in CNY-84.79m
  • Incorporated2000
  • Employees1.39k
  • Location
    Zhejiang Shapuaisi Pharmaceutical Co LtdLumianjin BridgeChengbei Road, Pinghu CityJIAXING 314200ChinaCHN
  • Phone+86 57 385021168
  • Fax+86 57 385076188
  • Websitehttp://www.zjspas.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ChengDu Sheng Nuo Biotec Co Ltd481.63m92.49m3.24bn1.13k34.973.53--6.730.82790.82794.318.200.34010.8623.96426,977.706.527.478.679.4459.9270.5219.1715.820.846613.350.3221.839.939.379.0818.6954.71--
Zhejiang Shapuaisi Pharmaceutical Co Ltd505.58m-84.79m3.50bn1.39k--2.08--6.93-0.2245-0.22451.344.440.24082.8613.81365,039.00-3.93-0.7573-4.52-0.871350.2958.02-16.32-2.451.04--0.1236--17.371.21-43.23--30.36--
Obio Technology Shanghai Corp Ltd251.68m-246.61m3.63bn731.00--1.94--14.41-0.3834-0.38340.39152.890.10124.002.55344,293.00-9.930.2246-11.170.2514-26.4236.72-98.161.482.27--0.1040.00-29.6935.88-425.90--57.00--
Hunan Warrant Pharmaceutical Co Ltd1.45bn211.45m3.70bn1.16k17.491.96--2.562.252.2515.4220.060.64261.499.741,244,707.008.3411.219.7914.0561.3269.0012.9813.963.18--0.05668.0510.8418.5015.6019.0224.49--
Data as of Nov 05 2024. Currency figures normalised to Zhejiang Shapuaisi Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
China Southern Asset Management Co., Ltd.as of 30 Jun 202422.20k0.01%
Orient Fund Management Co., Ltd.as of 30 Jun 20246.10k0.00%
China Universal Asset Management Co., Ltd.as of 30 Jun 20244.20k0.00%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20241.90k0.00%
Guotai Asset Management Co., Ltd.as of 30 Jun 20241.40k0.00%
E Fund Management Co., Ltd.as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.